Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions

Thomas Geisbert, Lisa E. Hensley

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Ebola virus (EBOV) gained public notoriety in the last decade largely as a consequence of the highly publicised isolation of a new EBOV species in a suburb of Washington, DC, in 1989, together with the dramatic clinical presentation of EBOV infection and high case-fatality rate in Africa (near 90% in some outbreaks), and the unusual and striking morphology of the virus. Furthermore, there are no vaccines or effective therapies currently available. Progress in understanding the origins of the pathophysiological changes that make EBOV infections of humans so devastating has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the mechanisms of EBOV pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. Notably, identifying factors triggering the haemorrhagic complications that characterise EBOV infections led to the development of a strategy to modulate coagulopathy; this therapeutic modality successfully mitigated the effects of EBOV haemorrhagic fever in nonhuman primates. This review summarises our current understanding of EBOV pathogenesis and discusses various approaches to therapeutic intervention based on our current understanding of how EBOV produces a lethal infection.

Original languageEnglish (US)
JournalExpert Reviews in Molecular Medicine
Volume6
Issue number20
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Ebolavirus
Ebola Hemorrhagic Fever
Viruses
Therapeutics
Life Cycle Stages
Primates
Disease Outbreaks
Vaccines
Mortality
Infection
Research
Life cycle

Keywords

  • Ebola virus
  • Filoviridae
  • Haemorrhagic fever
  • Pathogenesis
  • Therapy
  • Treatment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Molecular Medicine

Cite this

Ebola virus : New insights into disease aetiopathology and possible therapeutic interventions. / Geisbert, Thomas; Hensley, Lisa E.

In: Expert Reviews in Molecular Medicine, Vol. 6, No. 20, 09.2004.

Research output: Contribution to journalArticle

@article{bd306370dc7a40bebd0bfecec4311467,
title = "Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions",
abstract = "Ebola virus (EBOV) gained public notoriety in the last decade largely as a consequence of the highly publicised isolation of a new EBOV species in a suburb of Washington, DC, in 1989, together with the dramatic clinical presentation of EBOV infection and high case-fatality rate in Africa (near 90{\%} in some outbreaks), and the unusual and striking morphology of the virus. Furthermore, there are no vaccines or effective therapies currently available. Progress in understanding the origins of the pathophysiological changes that make EBOV infections of humans so devastating has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the mechanisms of EBOV pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. Notably, identifying factors triggering the haemorrhagic complications that characterise EBOV infections led to the development of a strategy to modulate coagulopathy; this therapeutic modality successfully mitigated the effects of EBOV haemorrhagic fever in nonhuman primates. This review summarises our current understanding of EBOV pathogenesis and discusses various approaches to therapeutic intervention based on our current understanding of how EBOV produces a lethal infection.",
keywords = "Ebola virus, Filoviridae, Haemorrhagic fever, Pathogenesis, Therapy, Treatment",
author = "Thomas Geisbert and Hensley, {Lisa E.}",
year = "2004",
month = "9",
doi = "10.1017/S1462399404008300",
language = "English (US)",
volume = "6",
journal = "Expert Reviews in Molecular Medicine",
issn = "1462-3994",
publisher = "Cambridge University Press",
number = "20",

}

TY - JOUR

T1 - Ebola virus

T2 - New insights into disease aetiopathology and possible therapeutic interventions

AU - Geisbert, Thomas

AU - Hensley, Lisa E.

PY - 2004/9

Y1 - 2004/9

N2 - Ebola virus (EBOV) gained public notoriety in the last decade largely as a consequence of the highly publicised isolation of a new EBOV species in a suburb of Washington, DC, in 1989, together with the dramatic clinical presentation of EBOV infection and high case-fatality rate in Africa (near 90% in some outbreaks), and the unusual and striking morphology of the virus. Furthermore, there are no vaccines or effective therapies currently available. Progress in understanding the origins of the pathophysiological changes that make EBOV infections of humans so devastating has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the mechanisms of EBOV pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. Notably, identifying factors triggering the haemorrhagic complications that characterise EBOV infections led to the development of a strategy to modulate coagulopathy; this therapeutic modality successfully mitigated the effects of EBOV haemorrhagic fever in nonhuman primates. This review summarises our current understanding of EBOV pathogenesis and discusses various approaches to therapeutic intervention based on our current understanding of how EBOV produces a lethal infection.

AB - Ebola virus (EBOV) gained public notoriety in the last decade largely as a consequence of the highly publicised isolation of a new EBOV species in a suburb of Washington, DC, in 1989, together with the dramatic clinical presentation of EBOV infection and high case-fatality rate in Africa (near 90% in some outbreaks), and the unusual and striking morphology of the virus. Furthermore, there are no vaccines or effective therapies currently available. Progress in understanding the origins of the pathophysiological changes that make EBOV infections of humans so devastating has been slow, primarily because these viruses require special containment for safe research. However, an increasing understanding of the mechanisms of EBOV pathogenesis, facilitated by the development of new tools to elucidate critical regulatory elements in the viral life cycle, is providing new targets that can be exploited for therapeutic interventions. Notably, identifying factors triggering the haemorrhagic complications that characterise EBOV infections led to the development of a strategy to modulate coagulopathy; this therapeutic modality successfully mitigated the effects of EBOV haemorrhagic fever in nonhuman primates. This review summarises our current understanding of EBOV pathogenesis and discusses various approaches to therapeutic intervention based on our current understanding of how EBOV produces a lethal infection.

KW - Ebola virus

KW - Filoviridae

KW - Haemorrhagic fever

KW - Pathogenesis

KW - Therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=24944465690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944465690&partnerID=8YFLogxK

U2 - 10.1017/S1462399404008300

DO - 10.1017/S1462399404008300

M3 - Article

C2 - 15383160

AN - SCOPUS:24944465690

VL - 6

JO - Expert Reviews in Molecular Medicine

JF - Expert Reviews in Molecular Medicine

SN - 1462-3994

IS - 20

ER -